TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17964576
Drug: Antinicotinic drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antinicotinic drug mecamylamine (MECA)
Study: 16569537
Drug: Temocapril (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temocapril (2 mg/d)
Study: 11135211
Drug: Doxorubicin 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 40 mg/m(2) and cyclophosphamide 600 mg/m(2) intravenously every 3 weeks (AC)
Study: 3932509
Drug: Controlled diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled diet supplemented with 2000 kCal and 10 g nitrogen daily (branched chain amino acid enriched formulation)
Study: 24503174
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (24IU)
Study: 28372849
Drug: Protein hydrolysate
Normalized name: Protein hydrolysate
DrugBank: Protein hydrolysate (DB09356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein hydrolysate drink (8.5 g before breakfast and 8.5 g before dinner)
Study: 20098520
Drug: Eszopiclone 3
Normalized name: eszopiclone 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eszopiclone 3 mg
Study: 24215127
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of ranibizumab (0.5 mg)
Study: 19756418
Drug: Tobramycin once
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin once daily (treatment B)
Study: 15837983
Drug: FEC 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC 100 (fluorouracil 500 mg/m2, cyclophosphamide 500 mg/m2, epirubicin 100 mg/m2)
Study: 9878641
Drug: Inhaled tobramycin
Normalized name: tobramycin Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled tobramycin (300 mg, twice daily for four weeks)
Study: 8924741
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (n=27)
Study: 7152080
Drug: Diprosalic lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diprosalic lotion (betamethasone dipropionate and salicylic acid)
Study: 7152080
Drug: Dermovate lotion
Normalized name: Dermovate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dermovate lotion (clobetasol propionate)
Study: 27161178
Drug: Dulaglutide 1.5
Normalized name: dulaglutide 1.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulaglutide 1.5 mg and 0.75 mg
Study: 27981279
Drug: Intra-articular platelet-rich
Normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular platelet-rich plasma (PRP) (3 ml)
Study: 18242485
Drug: Adenosine infusion
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine infusion (140 microg/kg/min)
Study: 26173463
Drug: Mandibular implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular implant fixed partial prostheses (IFPP)
Study: 26173463
Drug: Mandibular implant-supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular implant-supported overdenture (ISOD)
Study: 25005327
Drug: golimumab 100
Normalized name: golimumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: golimumab 100 mg + MTX
Study: 22386826
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg commercial sildenafil (reference)
Study: 16195581
Drug: Milk fermented
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk fermented with Lactobacillus acidophilus strain L-92 (L-92), 100 ml, containing 5 x 10(10) bacteria, twice a day for 6 weeks
Study: 9475563
Drug: Salmeterol 50
Normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 50 microg inhaled at bedtime followed by unblinded salmeterol 50 microg inhaled 12 hours later
Study: 9475563
Drug: Placebo inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhaled at bedtime followed by unblinded salmeterol 50 microg inhaled 12 hours later
Study: 1082238
Drug: Alternate day
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate day dose of vitamin A in addition to massive therapy
Study: 27155753
Drug: FP group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP group (100 μg b.i.d.)
Study: 22258708
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of 30 μg HA
Study: 22258708
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of 15 μg HA for elderly
Study: 3899506
Drug: Oral contraception
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraception
Study: 17998491
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of strength training and Fibromyalgia Self‐Help Course (ST-FSHC)
Study: 17998491
Drug: Exercise alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise alone and in combination with education
Study: 2268533
Drug: Concurrent intrathecal
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent intrathecal methotrexate therapy
Study: 2268533
Drug: No concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: No concurrent intrathecal methotrexate therapy
Study: 26228322
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of cefuroxime sodium and metronidazole (Group A)
Study: 26228322
Drug: Repeated dose
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated dose of cefuroxime sodium and metronidazole (Group B)
Study: 22619107
Drug: Sustained virological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained virological response (SVR) after PEG‐IFNα2a/RBV or PEG‐IFNα2b/RBV treatment
Study: 22619107
Drug: Treatment failure
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment failure (non-SVR)
Study: 17519217
Drug: Narrowband-UV-B (NB‐UVB)
Normalized name: Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrowband-UV-B (NB‐UVB) therapy
Study: 11513170
Drug: Eradication treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication treatment
Study: 9685916
Drug: Soft gelatin
Normalized name: Norvir Soft Gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft gelatin capsule containing PEG 400 suspension of gliclazide
Study: 9685916
Drug: Diamicron (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diamicron (conventional tablet)
Study: 2985658
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg tid increased to 100 mg tid)
Study: 2985658
Drug: Methyldopa (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa (250 mg to 500 mg bid and 1,000 mg bid)
Study: 30882578
Drug: Postoperative Radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative Radiation Therapy (PR group) with 150 mg/m/wk intra-arterial cisplatin for 4 weeks followed by radiotherapy
Study: 30882578
Drug: Definitive Radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Definitive Radiation Therapy (DR group) with 150 mg/m/wk intra-arterial cisplatin for 4 weeks followed by definitive radiotherapy
Study: 22983924
Drug: Topiramate (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (maximum dose of 75 mg)
Study: 10754735
Drug: No thrombolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No thrombolytic therapy
Study: 9305335
Drug: Gabapentin 600
Normalized name: gabapentin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 600 mg/d
Study: 9305335
Drug: Gabapentin 1200
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 1200 mg/d
Study: 17568397
Drug: Cocaine (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (0, 12, 25, and 50 mg)
Study: 15036550
Drug: Gabapentin (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (0 mg/d)
Study: 11751775
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (CI) of ceftazidime 1 g iv followed by a 4.5 g CI over 24 h
Study: 11751775
Drug: 8-hourly administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-hourly administration of ceftazidime 1.5 g tds
Study: 363333
Drug: Metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 100 mg twice daily + Chlorthalidone 50 mg daily
Study: 31120272
Drug: No Treatment
Normalized name: NO
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No Treatment (NT) control
Study: 28031021
Drug: Usual physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual physical therapy
Study: 19593175
Drug: OFC (olanzapine/fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: OFC (olanzapine/fluoxetine combination)
Study: 15261700
Drug: Second treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second treatments (real or sham)
Study: 16181532
Drug: Astragalus injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astragalus injection (AI)
Study: 9204358
Drug: Iopentol (Imagopaque
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopentol (Imagopaque 350 mg I/ml)
Study: 9204358
Drug: Diatrizoate (Urografin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diatrizoate (Urografin 370 mg I/ml)
Study: 2927976
Drug: Bennett‐Twin nebulizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bennett‐Twin nebulizer (output 0.31 ml/min, nebulization time 1 min)
Study: 2927976
Drug: Wright nebulizer
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wright nebulizer (output 0.15 ml/min, nebulization time 2 min)
Study: 2927976
Drug: Wright nebulizer
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wright nebulizer driven by a flow rate of 12 L/min (output 0.30 ml/min, nebulization time 1 min)
Study: 31885071
Drug: RBC transfusion
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC transfusion at a Hb threshold of 7 g/dl
Study: 31885071
Drug: RBC transfusion
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC transfusion at a Hb threshold of 9 g/dl
Study: 28264612
Drug: Ingenol disoxate
Normalized name: Ingenol disoxate
DrugBank: Ingenol disoxate (DB15109)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingenol disoxate 0.018% gel
Study: 21806518
Drug: Integrated cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated cognitive behaviour therapy and motivational interviewing (CBT/MI) delivered by a therapist
Study: 21806518
Drug: Person-centred therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Person-centred therapy (PCT) - control group
Study: 19329193
Drug: Daytime intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daytime intravenous glucocorticoid treatment
Study: 19329193
Drug: Nighttime intravenous
Normalized name: Flonase Nighttime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nighttime intravenous glucocorticoid treatment
Study: 2679269
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment protocols
Study: 16886837
Drug: Sarpogrelate 200
Normalized name: Sarpogrelate
DrugBank: Sarpogrelate (DB12163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarpogrelate 200 mg bid
Study: 16886837
Drug: Sarpogrelate 200
Normalized name: Sarpogrelate
DrugBank: Sarpogrelate (DB12163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarpogrelate 200 mg tid
Study: 15236142
Drug: Nebulized adrenaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized adrenaline (3 mg)
Study: 8422235
Drug: No drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drugs or a current of reverse polarity applied
Study: 8422235
Drug: Electric currents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electric currents (3.5-5.0 mA) applied for 20 min to 10 solutions in cadaveric bladders
Study: 2878678
Drug: Bufuralol 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bufuralol 7.5 mg
Study: 2878678
Drug: Bufuralol 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bufuralol 60 mg
Study: 2878678
Drug: Bufuralol 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bufuralol 120 mg
Study: 26404425
Drug: Spray cryotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray cryotherapy
Study: 20329382
Drug: Standard MDT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard MDT + once a month supervised 100 mg of Minocycline and 400 mg of Ofloxacin for 12 months
Study: 12973820
Drug: Modified-release methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-release methylphenidate (Ritalin LA) 40 mg administered intact with a high-fat breakfast
Study: 12973820
Drug: Modified-release methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-release methylphenidate (Ritalin LA) 40 mg sprinkled on applesauce
Study: 11885169
Drug: Hydroxyapatite (HA)‐coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyapatite (HA)‐coated implants
Study: 11885169
Drug: Non‐coated implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non‐coated implants
Study: 11885169
Drug: Non‐coated implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non‐coated implants in bone quality 3
Study: 9003951
Drug: 5% oxatomide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% oxatomide gel
Study: 9003951
Drug: Placebo (petrolatum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (petrolatum ointment)
Study: 1510262
Drug: Physiologic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiologic saline solution (placebo group)
Study: 6239548
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia applied to the fallopian tubes
Study: 1422291
Drug: No topical
Normalized name: Altreno Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No topical anesthesia
Study: 25833784
Drug: Mamba (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mamba (50 g, 260 kcal, >75% of RDA for critical micronutrients)
Study: 25833784
Drug: Tablet Yo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet Yo (42 g, 165 kcal)
Study: 17408017
Drug: Ketoconazole (KTZ)
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole (KTZ) at a 600 mg/day maintenance dose for periods ranging from 15 days to 13 years.
Study: 7517829
Drug: Intensive drug
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive drug treatment (combinations of colestipol, nicotinic acid and lovastatin)
Study: 7517829
Drug: Diet and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet and modest doses of colestipol (Control)
Study: 7517829
Drug: Diet and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet and lovastatin (up to 80 mg daily)
Study: 7517829
Drug: Intensive drug
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive drug treatment (in women)
Study: 3139326
Drug: Intravenous nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nitroglycerin (NG) therapy
Study: 31777235
Drug: 10-time electroacupuncture
Normalized name: Return 10 TIME LOCK PROGRAM KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-time electroacupuncture treatment (once a day for 10 times)
Study: 31777235
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between 5-time and 10-time treatment groups
Study: 28502496
Drug: SC401 (1530
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC401 (1530 mg omega-3 fatty acids EE) under fasted conditions
Study: 28502496
Drug: SC401 (1530
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC401 (1530 mg omega-3 fatty acids EE) under low-fat meal conditions
Study: 28502496
Drug: SC401 (1530
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC401 (1530 mg omega-3 fatty acids EE) under high-fat meal conditions
Study: 28502496
Drug: SC401 (1530
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC401 (1530 mg omega-3 fatty acids EE) under low-fat/high-fat meal conditions
Study: 14644393
Drug: Rosuvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (40 mg/day for 8 weeks)
Study: 10770982
Drug: Pegvisomant 10
Normalized name: pegvisomant 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegvisomant 10 mg
Study: 10770982
Drug: Pegvisomant 15
Normalized name: pegvisomant 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegvisomant 15 mg
Study: 10770982
Drug: Pegvisomant 20
Normalized name: pegvisomant 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegvisomant 20 mg
Study: 9384476
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy and autologous stem cell transplantation
Study: 9384476
Drug: Conventional-dose salvage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose salvage therapy prior to high-dose therapy
Study: 9796516
Drug: Combination inferior
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination inferior alveolar nerve block plus incisive nerve block
Study: 4010949
Drug: Levamisole 150
Normalized name: levamisole 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole 150 mg
Study: 31348349
Drug: Hand therapy
Normalized name: Octinoxate 3.00 mL in 75 mL / Avobenzone 1.5 mL in 75 mL TOPICAL CREAM [Botanics Daily Hand Therapy Sunscreen SPF 10]
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hand therapy (supervised sessions and home exercises); mean 9.2 sessions over 14.2 weeks
Study: 28760939
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (<140 mmHg)
Study: 27983572
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (200 µg daily for six weeks)
Study: 19570717
Drug: Tonabersat 40
Normalized name: Tonabersat
DrugBank: Tonabersat (DB06578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tonabersat 40 mg once daily
Study: 8608684
Drug: Aceclofenac (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aceclofenac (100 mg twice daily)
Study: 22462425
Drug: Diclofenac (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (75 mg twice daily)
Study: 31412955
Drug: NI-03 (camostat
Approvals — FDA: no, EMA: no, PMDA: no
Description: NI-03 (camostat mesilate) administered three times daily at doses of 100, 200, or 300 mg for 28 days
Study: 22453316
Drug: Docusate sodium
Normalized name: Docusate Sodium
DrugBank: Docusate (DB11089)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docusate sodium plus Miralax, fiber wafers, and bisacodyl suppositories
Study: 10613592
Drug: EPO plus
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO plus G-CSF combination after PBPCT
Study: 386390
Drug: Amitriptyline (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (150 mg/d)
Study: 8600497
Drug: Acetaminophen (2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (2,000 mg/d)
Study: 2007941
Drug: Ceftriaxone, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone, 50 mg/kg per day for 5 days
Study: 2007941
Drug: Ampicillin, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin, 100 mg/kg per day for 5 days
Study: 7102737
Drug: No introduction
Approvals — FDA: no, EMA: no, PMDA: no
Description: No introduction with oral presentation
Study: 28831548
Drug: Azathioprine (AZA)
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine (AZA) 50 mg/day oral, increased to 2-3 mg/kg/day with oral prednisolone as adjunctive therapy
Study: 28831548
Drug: Rituximab (RIT)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (RIT) 1 g intravenous, repeated 2 weeks later and then every 6 months
Study: 21303732
Drug: OROS-methylphenidate (OROS-MPH),
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS-methylphenidate (OROS-MPH), mean daily dose 84.6±31.6 mg (1.04±0.29 mg/kg)
Study: 21303732
Drug: Placebo, mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, mean daily dose 100.5±21.9 mg (1.20±0.11 mg/kg)
Study: 19530576
Drug: Standard rescue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard rescue drugs (Tramadol)
Study: 19530576
Drug: Diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 75 mg intramuscular every 12 hours for 2 doses
Study: 12901874
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (250 mg/day)
Study: 1680327
Drug: Salbutamol (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (0.1 mg) in customary metered-dose inhaler
Study: 1680327
Drug: Pirbuterol (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirbuterol (0.2 mg) in Autohaler
Study: 7040820
Drug: Chemoimmunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoimmunotherapy with DTIC plus intradermal BCG
Study: 7040820
Drug: Methyl‐CCNU plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyl‐CCNU plus intradermal BCG
Study: 29094315
Drug: Umeclidinium/Vilanterol (UMEC/VI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 µg once daily
Study: 29094315
Drug: Tiotropium/Olodaterol (TIO/OLO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium/Olodaterol (TIO/OLO) 5/5 µg once daily
Study: 26433562
Drug: Reduced standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced standard treatment combined with the computer‐based therapeutic education system (TES)
Study: 15598196
Drug: Standard methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard methadone maintenance treatment
Study: 23713301
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (clomifene and HCG)